PHARMACY TIMES

BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT

September 2, 2022

August 2022 P&T Update

The following tables detail changes that were approved by the Pharmacy and Therapeutics Subcommittee in August 2022.

For any questions, suggestions, or if you would like a printed copy of the IEHP Formulary Book or Clinical Practice Guideline, please call us at (909) 890-2049. As a reminder, the updated formulary information and Clinical Practice Guidelines are available at www.iehp.org.

Sincerely,
IEHP Pharmaceutical Services

NOTE: IEHP is a generic mandated health plan. Brand name drugs are not covered unless indicated or if generic is not available. The FDA recommended maximum dosage limit is applied.

IEHP Medicare Pharmacy Benefit Formulary Updates

We would like to inform you of the following changes to the **2022 IEHP Medicare Formulary** that were approved by the Pharmacy and Therapeutics Subcommittee in August 2022.
As a reminder, all **Medi-Cal** formulary decisions are no longer made by IEHP and should be addressed with **Medi-Cal Rx** directly.

***Legend for Status Change column**

AF = Add to Formulary	**AR** = Age Restriction
BOLD = Brand Name	**C1** = Code 1 drugs are restricted to certain medical conditions or specific circumstances
DS = Days' Supply	**PA** = Prior Authorization
QL = Quantity Limit	**RF** = Remove from Formulary
ST = Step Therapy	**R-PA** = Remove Prior Authorization
R-QL = Remove Quantity Limit	**R-C1 =** Remove Code 1 restriction **RSOC =** Remove Site of Care

IEHP Medicare Pharmacy Benefit Formulary Updates Effective 09/02/2022		
Drug Name	**Strength & Dosage Form**	**Status Change***
abacavir-lamivudine-zidovudine	300 mg-150 mg-300 mg tablet	• RF
apomorphine	10 mg/mL subcutaneous cartridge	• AF • PA
Apokyn (apomorphine)	10 mg/mL subcutaneous cartridge	• RF
aztreonam	2 gm solution for injection	• AF
betaine	1 mg/scoop oral powder	• AF
Chantix (varenicline)	Starting Month Box 0.5 mg (11) – 1 mg (42) tablets in dose pack; Continuing Month Box 1 mg tablet; 0.5 mg tablet; 1 mg tablet	• RF
Cimduo (lamivudine and tenofovir disoproxil fumarate)	300 mg-300 mg tablet	• AF • QL = 1/1 ds
Copiktra (duvelisib)	15 mg capsule; 25 mg capsule	• RF
cyclosporine	0.05% eyedrops in a dropperette	• AF • QL = 2/1 ds
Cystadane (betaine anhydrous for oral solution)	1 gm/1.7 mL oral powder	• RF
Esbriet (pirfenidone)	267 mg tablet, 801 mg tablet	• RF
Farydak (panobinostat)	10 mg capsule; 15 mg capsule; 20 mg capsule	• RF

fluticasone furoate-vilanterol	100 mcg-25 mcg/dose inhalation powder; 200 mcg-25 mcg/dose inhalation powder	• AF • QL 2/1 ds
fluticasone propionate	44 mcg/actuation HFA aerosol inhaler; 110 mcg/actuation HFA aerosol inhaler; 220 mcg/actuation HFA aerosol inhaler	• AF • QL (44 mcg) = 0.36/1 ds • QL (110 mcg) = 0.4/1 ds • QL (220 mcg) = 0.8/1 ds
GaviLyte-N (polyethylene glycol 3350)	420 gm oral solution	• RF
glycopyrrolate	1.5 mg tablet	• AF
Kinrix (PF) (diphtheria, pertussis acellular, polio, tetanus vaccine)	25 Lf-58 mcg-10Lf/0.5 mL intramuscular suspension	• RF
lacosamide	10 mg/mL oral solution; 50 mg tablet; 100 mg tablet; 150 mg tablet; 200 mg tablet	• AF • PA (New Starts) • QL (oral soln) = 40/1 ds • QL (tablet) = 2/1 ds
lenalidomide	5 mg capsule; 10 mg capsule; 15 mg capsule; 25 mg capsule	• AF • PA (New Starts)
lithium citrate	8 mEq/5 mL oral solution	• RF
maraviroc	300 mg tablet	• AF • QL = 4/1 ds
ondansetron HCl	24 mg tablet	• RF
pirfenidone	267 mg tablet; 801 mg tablet	• AF • PA • QL (267 mg) = 9/1 ds • QL (801 mg) = 3/1 ds
Prehevbrio (PF) (Hepatitis B vaccine (recombinant))	10 mcg/mL intramuscular suspension	• PA (BvD)
Previfem (norgestimate and ethinyl estradiol)	0.25 mg-35 mcg tablet	• RF
Quadracel (PF) (influenza vaccine)	15 Lf-48 mcg-5 Lf unit/0.5 mL intramuscular suspension	• AF
Restasis	0.05% eye drops in a dropperette	• AF • QL = 2/1 ds
Restasis MultiDose	0.05% eye drops	• AF
Revlimid (lenalidomide)	5 mg capsule; 10 mg capsule; 15 mg capsule, 25 mg capsule	• RF
Rinvoq (upadacitinib)	45 mg tablet, extended release	• AF • PA • QL =1/1 ds
Selzentry (maraviroc)	200 mg tablet	• RF
Temixys (lamivudine and tenofovir disoproxil fumarate)	300 mg-300 mg tablet	• RF
Triumeq PD (abacavir, dolutegravir, and lamivudine)	60 mg-5 mg-30 mg tablet for oral suspension	• AF • QL = 10/1 ds
Trizivir (abacavir, lamivudine, and zidovudine)	300 mg-150 mg-300 mg tablet	• AF

		• QL = 2/1 ds
Ukoniq (umbralisib)	200 mg tablet	• RF
varenicline	0.5 mg (11)-1 mg (42) tablets in a dose pack	• AF
Vimpat (lacosamide)	10 mg/mL oral solution; 50 mg tablet; 100 mg tablet; 150 mg tablet; 200 mg tablet	• RF
Vonjo (pacritinib)	100 mg capsule	• AF • PA (New Starts) • QL = 2/1 ds
Xiidra (lifitegrast ophthalmic solution)	5% eye drops in a dropperette	• AF • QL = 2/1 ds

Inland Empire Health Plan

IEHP Medi-Cal Medical Drug Benefit (RxUM) Formulary Updates

We would like to inform you of the following changes to the **2022 IEHP Medi-Cal Medical Drug Benefit (RxUM) Formulary** that were approved by the Pharmacy and Therapeutics Subcommittee in August 2022.
As a reminder, all **Medi-Cal** Pharmacy Benefit formulary decisions are no longer made by IEHP and should be addressed with **Medi-Cal Rx** directly.

***Legend for Status Change column**

AF = Add to Formulary	**AR** = Age Restriction
BOLD = Brand Name	**C1** = Code 1 drugs are restricted to certain medical conditions or specific circumstances
DS = Days' Supply	**PA** = Prior Authorization
QL = Quantity Limit	**RF** = Remove from Formulary
ST = Step Therapy	**R-PA** = Remove Prior Authorization
R-QL = Remove Quantity Limit	**R-C1 =** Remove Code 1 restriction **RSOC =** Remove Site of Care

IEHP Medi-Cal Medical Drug Benefit (RxUM) Formulary Updates Effective 09/01/2022			
Code	**Drug Name**	**Strength & Dosage Form**	**Status Change***
J0131	acetaminophen	10 mg injection	• AF
J0221	**Lumizyme** (alglucosidase-alfa)	10 mg injection	• RSOC
J0330	succinylcholine chloride	(up to) 20 mg injection	• AF
J0456	azithromycin	500 mg injection	• AF
J0640	leucovorin calcium	per 50 mg injection	• Remove PA
J0885	epoetin alfa (for non-ESRD use)	1000 units injection	• AF • PA • Tier 2
J1442	filgrastim (G-CSF) (hematology/oncology)	1 mcg injection	• AF • Excludes biosimilars
J1569	**Gammagard liquid** (immune globulin)	500 mg non-lyophilized injection (e.g., liquid)	• AF • PA

Code	Drug Name	Strength & Dosage Form	Status Change*
J1745	infliximab	10 mg injection	• AF • PA • Tier 2
J2326	nusinersen	0.1 mg injection	• RSOC
J2353	octreotide	1 mg injection, depot form for intramuscular injection	• AF • PA
J2370	phenylephrine HCl	(up to) 1 ml injection	• AF
J2506	pegfilgrastim (hematology/oncology)	0.5 mg injection	• AF • Excludes biosimilars
J2704	propofol	10 mg injection	• AF
J2916	sodium ferric gluconate complex in sucrose	12.5 mg injection	• AF
J3240	thyrotropin (diagnostic drugs)	injection	• AF
J3241	teprotumumab-trbw	10 mg injection	• RSOC
J3315	triptorelin pamoate (hematology/oncology)	injection	• AF
J3489	zoledronic acid	1 mg injection	• Remove PA
J9035	bevacizumab	10 mg injection	• Remove PA (bevacizumab) • AF (antineoplastic) • PA (antineoplastic) • AF (ophthalmology)
J9041	**Velcade** (bortezomib)	0.1 mg injection	• AF • PA (bortezomib)
J9130	dacarbazine	100 mg powder for injection	• AF • PA (antineoplastic)
J9181	etoposide	10 mg for injection	• AF • PA (antineoplastic)
J9202	gosereline acetate	implant	• AF (hematology/oncology)
J9209	mesna	200 mg for injection	• AF
J9217	leuprolide acetate	for suspension	• AF (hematology/oncology)
J9264	paclitaxel protein-bound particles	1 mg for injection	• AF • PA (antineoplastic)
J9305	pemetrexed NOS	10 mg for injection	• AF • PA (antineoplastic)
J9312	rituximab	10 mg for injection	• Remove PA (bevacizumab) • AF • PA (hem/oncology) • AF (ophthalmology)
J9354	ado-trastuzumab emtansine	1 mg for injection	• RSOC

Code	Drug Name	Strength & Dosage Form	Status Change*
J9355	trastuzumab	10 mg for injection	• AF • PA (antineoplastic) • Excludes biosimilars • Tier 2
J9360	vinblastine sulfate	1 mg for injection	• AF • PA (antineoplastic)
J9370	vincristine sulfate	1 mg	• AF • PA (antineoplastic)
J9395	fulvestrant	25 mg for injection	• AF • PA (antineoplastic)
Q0162	ondansetron	1 mg, oral	• AF
Q2041	axicabtagene ciloleucel	up to 200 million autologous anti-cd19 car positive viable t-cells, including leukapheresis and dos preparation procedures, per therapeutic dose	• RSOC
Q2042	tisagenlecleucel	up to 600 million car-positive viable t-cells, including leukapheresis and dose preparation procedures per therapeutic dose	• RSOC
Q2053	brexucabtagene autoleucel	up to 200 million autologous anti-cd19 car positive viable t-cells, including leukapheresis and dose preparation procedures, per therapeutic dose	• ROSC
Q2054	lisocabtagene maraleucel	up to 110 million autologous anti-cd19 car-positive viable t-cells, including leukapheresis and dose preparation procedures, per therapeutic dose	• RSOC
Q2055	Idecabtagene vicleucel	up to 460 million autologous b-cell maturation antigen (bcma) directed car-positive t-cells, including leukapheresis and dose preparation procedures, per therapeutic dose	• RSOC
Q5105	**Retacrit** epoetin alfa-epbx (biosimilar) for non-ESRD use)	1000 units for injection	• AF (hematology/oncology)
Q5113	**Herzuma** trastuzumab-pkrb (biosimilar)	10 mg injection	• RSOC
Q5114	**Ogivri** (trastuzumab-dkst) (biosimilar)	10 mg for injection	• RSOC
Q5117	**Kanjinti** ado-trastuzumab-anns (biosimilar)	10 mg for injection	• RSOC
Q5118	**Zirabev** bevacizumab-bvzr (biosimilar)	10 mg for injection	• Restrict to Hematology/Oncology

Medicare Indication, Formulation, and Molecular Entity Updates by Drug	
Drug Name	**Updated Information**
Adlarity (donepezil)	**NEW ROUTE AND DOSAGE FORM** • Adlarity is an acetylcholinesterase inhibitor indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type
Alymsys (bevacizumab-maly)	**NEW BIOSIMILAR (AVASTIN)** • Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of (1) Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment (2) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen (3) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment (4) Recurrent glioblastoma in adults (5) Metastatic renal cell carcinoma in combination with interferon alfa (6) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan (7) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens.
Amvuttra (vutrisiran)	**NEW MOLECULAR ENTITY** • Amvuttra is a transthyretin-directed small interfering RNA indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Aspruzyo Sprinkle (ranolazine)	**NEW DOSAGE FORM** • Aspruzyo Sprinkle is an antianginal indicated for the treatment of chronic angina.
Beovu (brolucizumab-dbll)	**NEW INDICATION AND DOSAGE FORM** • Beovu is a human vascular endothelial growth factor inhibitor indicated for the treatment of Diabetic Macular Edema.
bortezomib	**NEW STRENGTHS** • Bortezomib for injection is a proteasome inhibitor indicated for (1) treatment of adult patients with multiple myeloma (2) treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.
Breyanzi (lisocabtagene maraleucel)	**NEW INDICATIONS** • Breyanzi is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have (1) refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy (2) refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation due to comorbidities or age.
Byooviz (ranibizumb-nuna)	**NEW BIOSIMILAR (LUCENTIS)** • Byooviz, a vascular endothelial growth factor inhibitor, is indicated for the treatment of patients with (1) Neovascular (Wet) Age-Related Macular Degeneration (AMD) (2) Macular Edema following retinal vein occlusion (3) Myopic choroidal neovascularization.
Camcevi (leuprolide injectable emulsion)	**NEW STRENGHT AND FORMULATION** • Camcevi is a gondotropin-releasing hormone agonist indicated for the treatment of adult patients with advanced prostate cancer.

Camzyos (mavacamten)	**NEW MOLECULAR ENTITY** • Camzyos is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
Cellcept (mycophenolate mofetil)	**NEW PATIENT POPULATION** • Cellcept is an antimetabolite immunosuppressant indicated for the prophylaxis of organ Rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart, or liver transplants in combination with other immunosuppressants.
Comirnaty (COVID-19 Vaccine, mRNA)	**NEW PATIENT POPULATION** • Comirnaty is a vaccine indicted for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.
Diacomit (stiripentol)	**NEW PATIENT POPULATION** • Diacomit is indicated for the treatment of seizures associated with Dravet syndrome in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more.
Dupixent (dupilumab)	**NEW INDICATION** • Dupixent is an interleukin-4 receptor alpha antagonist indicated for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis.
Dupixent (dupilumab)	**NEW PATIENT POPULATION** • Dupixent is an interleukin-4 receptor alpha antagonist indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Dyanavel XR (amphetamine)	**NEW DOSAGE FORM** • Dyanavel XR is a central nervous system stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.
Enhertu (fam-trastuzumab deruxtecan-nxki)	**REGULAR APPROVAL (previously accelerated approval)** • Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either (1) in the metastatic setting, or (2) in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.
Epsolay (benzoyl peroxide)	**NEW INDICATION** • Epsolay is indicated for the treatment of inflammatory lesions of rosacea in adults.
Evrysdi (risdiplam)	**NEW PATIENT POPULATION** • Evrysdi is a survival of motor neuron 2 splicing modifier indicated for the treatment of spinal muscular atrophy in pediatric and adult patients.
Fluad Quad, Fluarix Quad, Afluria Quad, Fluzone Quad, Flublok Quad, Flucelvax Quad 2022-2023 (influenza vaccine)	**NEW MOLECULAR ENTITIES** • Influenza vaccines are indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
Fluzone High-Dose Quad 2022-2023 (influenza vaccine)	**NEW MOLECULAR ENTITY** • Influenza vaccines are indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
hydrocortisone acetate and pramoxine hydrochloride	**NEW DOSING FORM AND STRENGTH** • Hydrocortisone acetate and pramoxine hydrochloride suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani.
Hyftor (sirolimus)	**NEW ROUTE OF ADMINISTRATION, NEW DOSAGE FORM, AND NEW STRENGTH** • Hyftor is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.

Igalmi (dexmedetomidine hydrochloride)	**NEW ROUTE OF ADMINISTRATION, NEW DOSAGE FORM, AND NEW STRENGTH** • Igalmi is an alpha2-adrenergic receptor agonist indicated in adults for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder.
Imcivree (setmelanotide)	**NEW INDICATION** • Imcivree is a melanocortin 4 receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome.
Kymriah (tisgenlecleucel)	**NEW INDICATION** • Kymriah is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Kyprolis (carfilzomab)	**NEW INDICATION** • Kyprolis is a proteasome inhibitor that is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with isatuximab and dexamethasone.
Lyvispah (baclofen)	**NEW DOSAGE FORM** • Lyvispah is a gamma-aminobutyric acid agonist indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Lyvispah may also be of some value in patients with spinal cord injuries and other spinal cord diseases.
Mekinist (trametinib)	**NEW INDICATION** • Mekinist is a kinase inhibitor indicated, in combination with dabrafenib for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.
Mounjaro (tirzepatide)	**NEW MOLECULAR ENTITY** • Mounjaro is a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist indicted as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Norliqva (amlodipine)	**NEW DOSAGE FORM AND NEW STRENGTH** • Norliqva is a calcium channel blocker for the treatment of (1) Hypertension in adults and children 6 years of age and older, to lower blood pressure (2) Coronary artery disease (a) Chronic stable angina (b) Vasospastic angina (Prinzmetal's or Variant Angina) (c) angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%.
Nucala (mepolizumab)	**NEW STRENGTH** • Nucala is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) indicated for (1) add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype (2) add-on maintenance treatment of adult patients 18 years and older with chronic rhinosinusitis with nasal polyps (3) the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (4) the treatment of adult and pediatric patients aged 12 years and older with hyper-eosinophilic syndrome for ≥ 6 months without an identifiable non-hematologic secondary cause.
Olumiant (baricitinib)	**NEW DRUG INDICATION AND NEW STRENGTH** • Olumiant is a Janus kinase inhibitor indicated for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
Olumiant (baricitinib)	**NEW DRUG INDICATION** • Olumiant is a Janus kinase inhibitor indicated for the treatment of adult patients with severe alopecia areata.
Opdivo (nivolumab)	**NEW INDICATION** • Opdivo is a programmed death receptor-1 blocking antibody indicated for the adjuvant treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy.

pemetrexed disodium	**NEW FORMULATION** • Pemetrexed injection is a folate analog metabolic inhibitor indicated (1) in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. (2) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, NSCLC. (3) as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. (4) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. (5) initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.
pemetrexed	**NEW DOSE FORM (lyophilized powder)** • Pemetrexed for injection is a folate analog metabolic inhibitor indicated (1) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC). (2) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. (3) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. (4) initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.
Posimir (bupivacaine)	**NEW STRENGTH** • Posimir is indicated in adults for administration into the subacromial space under direct arthroscopic visualization to produce post-surgical analgesia for up to 72 hours following arthroscopic subacromial decompression.
Priorix (measles, mumps, and rubella vaccine, live)	**NEW FORMULATION** • Priorix is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.
Qelbree (viloxazine)	**NEW PATIENT POPULATION** • Qelbree is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
Qsymia (phentermine and topiramate)	**NEW PATIENT POPULATION** • Qsymia is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate, indicated as an adjunct to a reduced-caloric diet and increased physical activity for chronic weight management in pediatric patients aged 12 years and older with BMI in the 95th percentile or greater standardized for age and sex
Radicava ORS (edaravone)	**NEW ROUTE OF ADMINISTRATION, NEW DOSAGE FORM, AND NEW STRENGTH** • Radicava ORS is indicted for the treatment of amyotrophic lateral sclerosis.
Riabni (rituximab-arrx)	**NEW INDICATION** • Riabni is a CD20-directed cytolytic antibody indicated for the treatment of Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to-severely active RA who have inadequate response to one or more TNF antagonist therapies.
Rinvoq (upadacitinib)	**NEW INDICATION** • Rinvoq is a Janus kinase inhibitor indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.
Rubraca (rucaparib)	**REMOVAL OF INDICATION** • Rubraca is a poly (ADP-ribose) polymerase inhibitor indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and /or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.
Skyrizi (risankizumab-rzaa)	**NEW INDICATION AND STRENGTHS** • Skyrizi is an interleukin-23 antagonist indicated for the treatment of moderately to severely active Crohn's disease in adults.

Tafinlar (dabrafenib)	**NEW INDICATION** • Tafinlar is a kinase inhibitor indicated, in combination with trametinib, for the treatment of adults and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.
Tibsovo (ivosidenib)	**NEW INDICATION** • Tibsovo is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test in combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia is adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Ticovac (tick-borne encephalitis vaccine)	**NEW STRENGTH** • Ticovac is a vaccine indicated for active immunization to prevent tick-borne encephalitis. Ticovac is approved for use in individuals 1 year of age and older.
Tyvaso DPI (treprostinil)	**NEW DOSAGE FORM AND NEW STRENGTH** • Tyvaso DPI is a prostacyclin mimetic indicated for the treatment of (1) Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies with Tyvaso establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%) (2) Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study with Tyvaso establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis, combined pulmonary fibrosis and emphysema (25%), and WHO Group 3 connective tissue disease (22%).
Ultomiris (ravulizumab-cwvz)	**NEW INDICATION** • Ultomiris is a complement inhibitor indicated for the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive.
valsartan	**NEW DOSAGE FORM AND STRENGTH** • Valsartan is an angiotensin II receptor blocker indicated for (1) Hypertension in adults and children six years and older, to lower blood pressure. Heart failure (NYHA class II-IV); valsartan oral solution significantly reduces hospitalization for heart failure in patients who are unable to swallow valsartan tablets. (3) Stable left ventricular or left ventricular dysfunction following myocardial infarction; valsartan oral solution reduces cardiovascular mortality in patients who are unable to swallow valsartan tablets.
Veklury (remdesivir)	**NEW PATIENT POPULATION** • Veklury is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (28 days of age and older and weighing at least 3 kg) with positive results of direct SARS-CoV-2 viral testing, who are (1) hospitalized, or (2) not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.
Vidaza (azacitidine)	**NEW INDICATION** • Vidaza is a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia.
Vivioa (oteseconazole)	**NEW MOLECULAR ENTITY** • Vivioa is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential.
Voquenza Dual Pak (vonoprazan tablets and amoxicillin capsules)	**NEW MOLECULAR ENTITY AND NEW COMBINATION** • Voquezna Dual Pak, is a co-packaged product containing vonoprazan, a potassium-competitive acid blocker, and amoxicillin, a penicillin class antibacterial indicated for the treatment of Helicobacter pylori infection in adults.
Voquenza Triple Pak (vonoprazan tablets, amoxicillin capsules, and clarithromycin tablets)	**NEW MOLECULAR ENTITY AND NEW COMBINATION** • Voquezna Triple Pak, is a co-packaged product containing vonoprazan, a potassium-competitive acid blocker, amoxicillin, a penicillin class antibacterial, and clarithromycin, a macrolide antimicrobial, indicated for the treatment of Helicobacter pylori infection in adults.

Vtama (tapinarof)	**NEW MOLECULAR ENTITY** • Vtama cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
Xalkori (crizotinib)	**NEW INDICATION** • Xalkori is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor that is anaplastic lymphoma kinase positive.
Yervoy (ipilimumab)	**NEW INDICATION** • Yervoy is a human cytotoxic T-lymphocyte antigen 4-blocking antibody indicated for the treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab.
Zerbaxa (ceftolozane and tazobactam)	**NEW PATIENT POPULATION (for two indications)** • Zerbaxa (ceftolozane and tazobactam) is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible microorganisms: (1) Complicated intra-abdominal infections, used in combination with metronidazole, in adult and pediatric patients (birth to less than 18 years old). (2) Complicated urinary tract infections, including pyelonephritis, in adults and pediatric patients (birth to less than 18 years old).
Ztalmy (ganaxolone)	**NEW MOLECULAR ENTITY** • Ztalmy is a neuroactive steroid gamma-aminobutyric acid A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients 2 years of age and older.
Zulresso (brexanolone)	**NEW PATIENT POPULATION** • Zulresso is a neuroactive steroid gamma-aminobutyric acid A receptor positive modulator indicated for the treatment of postpartum depression in patients 15 years and older.

Prior Authorization table available at: www.iehp.org > For Providers > Pharmacy Services > Clinical Information > Prior Authorization Drug Treatment Criteria

IEHP Pharmacy Policies, Prior Authorization Criteria, and Drug Class Criteria	
Document	**Subcommittee Action**
Pharmacy Prior Authorization Criteria	
Erythropoiesis Stimulating Agent (ESA) **Immunoglobulins** **Therapeutic Agents in Rheumatic and Inflammatory Diseases**	• **Update** • **ESA:** Add **Epogen** and **Procrit** criteria with covered uses of anemia due to Chronic Kidney Disease (CKD), chemotherapy, and HIV Infection • **Immunoglobulins:** Addition of criteria to align with guideline updates; Combined Idiopathic Thrombocytopenic Purpura (ITP) in Pregnancy with ITP General • **Therapeutic Agents in Rheumatic and Inflammatory Diseases:** Retire Prior Authorization (PA) criteria for **Enbrel** (etanercept), **Humira** (adalimumab), and **Otezla** (apremilast); Renew PA criteria for **Rituxan** (rituximab)
Spinraza **Synagis**	• **Renew with no changes**
Hereditary Angioedema (HAE)	• **Retire** • **Rationale for retiring**: Pharmacy benefit carved out to Medi-Cal Rx; sufficient coverage with appropriate prior authorization criteria
Pharmacy Policy	
Intradialytic Parenteral Nutrition (IDPN) Therapy	• **Update** • Updated references; removed initial coverage criteria regarding weight and BMI
Discharge Medication **Off-Label Indication Policy**	• **Renew with no changes**